The tear production of tecovirimat in a single hospitalized mpox patient: a pharmacokinetic analysis

Stephen Woolley; Iheukwumere Duru; Luca Pagano; Rebecca Lester; Karen Devine; Shazaad Ahmad; Raqib Huq; Suzanne Marshall; Danielle McLaughlan; Mark Lavery; Elizabeth Challenger; Laura J Else; Malcolm G Semple; Stephen Kaye; Saye H Khoo; Mike Beadsworth

doi:10.1093/jac/dkaf071

The tear production of tecovirimat in a single hospitalized mpox patient: a pharmacokinetic analysis

Stephen Woolley, Iheukwumere Duru, Luca Pagano, Rebecca Lester, Karen Devine, Shazaad Ahmad, Raqib Huq, Suzanne Marshall, Danielle McLaughlan, Mark Lavery, Elizabeth Challenger, Laura J Else, Malcolm G Semple, Stephen Kaye, Saye H Khoo, Mike Beadsworth

Clinical Sciences

Liverpool School of Tropical Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Mpox is an orthopox DNA virus.1,2 Ophthalmic manifestations include preseptal cellulitis, conjunctivitis and keratitis, either as a primary or secondary viral infection or a secondary bacterial infection.2 Tecovirimat (Tpoxx) is an oral orthopox-specific drug that inhibits the orthopoxvirus VP37 envelope-wrapping protein and prevents the formation of egress-competent virions.3 There are limited pharmacokinetic/pharmacodynamic (PK/PD) data available. We present a case report of a critically unwell mpox patient, who had tecovirimat PK sampling of plasma and tears.

Original language	English
Pages (from-to)	1455-1457
Number of pages	3
Journal	Journal of Antimicrobial Chemotherapy
Volume	80
Issue number	5
Early online date	20 Mar 2025
DOIs	https://doi.org/10.1093/jac/dkaf071
Publication status	Published - 1 May 2025

Access to Document

10.1093/jac/dkaf071Licence: CC BY-NC

Dkaf071Final published version, 221 KBLicence: CC BY-NC

Cite this

Woolley, S., Duru, I., Pagano, L., Lester, R., Devine, K., Ahmad, S., Huq, R., Marshall, S., McLaughlan, D., Lavery, M., Challenger, E., Else, L. J., Semple, M. G., Kaye, S., Khoo, S. H., & Beadsworth, M. (2025). The tear production of tecovirimat in a single hospitalized mpox patient: a pharmacokinetic analysis. Journal of Antimicrobial Chemotherapy, 80(5), 1455-1457. https://doi.org/10.1093/jac/dkaf071

@article{689b3b4312b342a38221e1106156a16c,

title = "The tear production of tecovirimat in a single hospitalized mpox patient: a pharmacokinetic analysis",

abstract = "Mpox is an orthopox DNA virus.1,2 Ophthalmic manifestations include preseptal cellulitis, conjunctivitis and keratitis, either as a primary or secondary viral infection or a secondary bacterial infection.2 Tecovirimat (Tpoxx) is an oral orthopox-specific drug that inhibits the orthopoxvirus VP37 envelope-wrapping protein and prevents the formation of egress-competent virions.3 There are limited pharmacokinetic/pharmacodynamic (PK/PD) data available. We present a case report of a critically unwell mpox patient, who had tecovirimat PK sampling of plasma and tears.",

author = "Stephen Woolley and Iheukwumere Duru and Luca Pagano and Rebecca Lester and Karen Devine and Shazaad Ahmad and Raqib Huq and Suzanne Marshall and Danielle McLaughlan and Mark Lavery and Elizabeth Challenger and Else, \{Laura J\} and Semple, \{Malcolm G\} and Stephen Kaye and Khoo, \{Saye H\} and Mike Beadsworth",

year = "2025",

month = may,

day = "1",

doi = "10.1093/jac/dkaf071",

language = "English",

volume = "80",

pages = "1455--1457",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "5",

}

Woolley, S, Duru, I, Pagano, L, Lester, R, Devine, K, Ahmad, S, Huq, R, Marshall, S, McLaughlan, D, Lavery, M, Challenger, E, Else, LJ, Semple, MG, Kaye, S, Khoo, SH & Beadsworth, M 2025, 'The tear production of tecovirimat in a single hospitalized mpox patient: a pharmacokinetic analysis', Journal of Antimicrobial Chemotherapy, vol. 80, no. 5, pp. 1455-1457. https://doi.org/10.1093/jac/dkaf071

TY - JOUR

T1 - The tear production of tecovirimat in a single hospitalized mpox patient: a pharmacokinetic analysis

AU - Woolley, Stephen

AU - Duru, Iheukwumere

AU - Pagano, Luca

AU - Lester, Rebecca

AU - Devine, Karen

AU - Ahmad, Shazaad

AU - Huq, Raqib

AU - Marshall, Suzanne

AU - McLaughlan, Danielle

AU - Lavery, Mark

AU - Challenger, Elizabeth

AU - Else, Laura J

AU - Semple, Malcolm G

AU - Kaye, Stephen

AU - Khoo, Saye H

AU - Beadsworth, Mike

PY - 2025/5/1

Y1 - 2025/5/1

N2 - Mpox is an orthopox DNA virus.1,2 Ophthalmic manifestations include preseptal cellulitis, conjunctivitis and keratitis, either as a primary or secondary viral infection or a secondary bacterial infection.2 Tecovirimat (Tpoxx) is an oral orthopox-specific drug that inhibits the orthopoxvirus VP37 envelope-wrapping protein and prevents the formation of egress-competent virions.3 There are limited pharmacokinetic/pharmacodynamic (PK/PD) data available. We present a case report of a critically unwell mpox patient, who had tecovirimat PK sampling of plasma and tears.

AB - Mpox is an orthopox DNA virus.1,2 Ophthalmic manifestations include preseptal cellulitis, conjunctivitis and keratitis, either as a primary or secondary viral infection or a secondary bacterial infection.2 Tecovirimat (Tpoxx) is an oral orthopox-specific drug that inhibits the orthopoxvirus VP37 envelope-wrapping protein and prevents the formation of egress-competent virions.3 There are limited pharmacokinetic/pharmacodynamic (PK/PD) data available. We present a case report of a critically unwell mpox patient, who had tecovirimat PK sampling of plasma and tears.

U2 - 10.1093/jac/dkaf071

DO - 10.1093/jac/dkaf071

M3 - Article

SN - 0305-7453

VL - 80

SP - 1455

EP - 1457

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 5

ER -

The tear production of tecovirimat in a single hospitalized mpox patient: a pharmacokinetic analysis

Abstract

Access to Document

Fingerprint

Cite this